Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases

Nattokinase — the enzyme extracted from fermented soybeans — arrives with an unusually broad set of claims. This review compiles them, casting the compound as a potential single answer to problems usually treated with several different drugs.

Across in vitro, animal, and some human studies, the authors describe nattokinase breaking down clots, lowering blood pressure, reducing cholesterol, limiting platelet clumping, and protecting nerve tissue. The framing is provocative: one inexpensive natural compound covering ground that otherwise takes aspirin, a statin, and an antihypertensive combined.

The practical appeal is obvious — a cheap, low-side-effect oral option — and so is the status-quo friction the authors name, against a pharmaceutical model built on those separate drug classes.

Our rating is cautious. We score the evidence low: for all the breadth, much of it comes from small, open-label, or animal studies, with no large independent randomized trials confirming benefit on real clinical endpoints. Clinical significance scores higher on potential — a safe, affordable, multi-action agent would matter if it panned out — but the gap between “promising” and “proven” here is wide, and the sweeping single-compound framing runs well ahead of the human evidence.